On the other hand, increased invasion of gastric cancer cells can occur in response to oxaliplatin through ATXN2L up-regulation, known as the regulator of SGs, with the effect of EGF along with the PI3 / AKT signaling pathway (Lin et al., 2019). This evidence concerns the gene ATXN2L and gastric cancer.